BIOSENSORS INT'L GROUP, LTD. (B20) SGD 0.83
Dividend Yield(TTM) =
If you find any of the dividend record is wrong or duplicated, please contact me.
|2016||0.00%||SGD 0 ||-
||CASH OR SHARE
|2013||2.41%||SGD 0.02 ||USD0.02
Biosensors International Group, Ltd., an investment holding company, develops, manufactures, and markets various medical devices for interventional cardiology and critical care procedures in China, Japan, and internationally. The company operates in four segments: Interventional Cardiology, Critical Care, Cardiac Diagnostic, and Licensing Revenue. The Interventional Cardiology segment supplies proprietary drug-eluting stents, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMimics 3D, BioMatrix Flex, BioMatrix Flex BTK, BioMatrix NeoFlex, BioMatrix, Axxess, BioFreedom, Chroma, BioStream, BioPath, Gazelle, Juno, S-Stent, Powerline, Quadrature Link, and MultiPleat brands. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. This segment offers ACCUTRANS, a disposable blood pressure transducer system; BIOTRANS, a re-usable blood pressure transducer; Multi-Lumen central venous catheters for infant and adult patients to administer medication or fluids, obtain blood tests, and directly obtain cardiovascular measurements; Thermodilution and Pulmonary Artery catheters for pulmonary artery monitoring; Bipolar Pacing catheters for temporary transvenous cardiac pacing to support critical procedures in the catherization lab, CCU, and emergency room settings; Embolectomy catheters; and BIOTRAY devices. The Cardiac Diagnostic segment supplies medical imaging and clinical applications. The Licensing Revenue segment engages in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.